Condition: Neuromyelitis Optica Spectrum Disorders · Myasthenia Gravis · Multiple Sclerosis · Sponsor: Tianjin Huanhu Hospital
This is an open label, single-site, dose-escalation study in up to 12 participants with relapsed or refractory Neurological Autoimmune Diseases. This study aims to evaluate the safety and efficacy of the treatment with universal CD19/BCMA CAR T-cells.
This description comes directly from the study's public registry record.
Jialing Wu · 86-18622271026 · wywjl2009@hotmail.com
Guanen Zhou · 86-13920273016 · tjzge@163.com
Always discuss trial participation with your own doctor first.
| Tianjin Huanhu Hospital | Tianjin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06939166